DIRS.INFO The most relevant business & tech news

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

☆ Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
▼ + stars: | 2024-04-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge in New Jersey on Monday rejected Johnson & Johnson 's and Bristol Myers Squibb 's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the program is constitutional. J&J and Bristol Myers Squibb did not immediately respond to requests for comment on the ruling. J&J, Bristol Myers Squibb, Novo Nordisk and Novartis presented their oral arguments before Quraishi during the same hearing in March. That same month, a federal judge in Delaware rejected AstraZeneca's separate lawsuit challenging the negotiations. In Texas, a third federal judge tossed a separate lawsuit in February.

Persons: Johnson, Bristol Myers, Joe Biden's, Zahid Quraishi, Quraishi, Bristol Myers Squibb's, AstraZeneca's Organizations: Bristol, Bristol Myers Squibb, Biden, White, Supreme, Final, of New, Novo Nordisk, Novartis, Chamber of Commerce Locations: New Jersey, U.S, of New Jersey, Delaware, Texas, Ohio

☆ Novartis CEO: Here's why we boosted our full-year guidance
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Here's why we boosted our full-year guidanceVas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.

Persons: Vas Organizations: Novartis Locations: U.S

☆ Watch CNBC's full interview with Novartis CEO Vas Narasimhan on earnings and weight loss drugs
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Novartis CEO Vas Narasimhan on earnings and weight loss drugsVas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.

Persons: Vas Organizations: Novartis Locations: U.S

☆ Stocks making the biggest moves midday: Spotify, JetBlue, Danaher, General Motors and more
▼ + stars: | 2024-04-23 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +4 min

General Motors — Shares rose more than 4% after the automaker exceeded analysts' expectations for its first-quarter results . General Motors posted adjusted earnings of $2.62 per share on revenue of $43.01 billion. Danaher — The life sciences firm popped more than 7% after beating analysts' expectations for its first-quarter results. Spotify — The streaming music company surged 16% after easily topping earnings expectations . KeyBanc Capital Markets downgraded Sunnova Energy to sector weight from overweight, citing caution on residential solar names particularly ahead of first-quarter earnings.

Persons: General Motors, JetBlue's, LSEG, Nucor, Danaher, Sherwin, Williams, Sunnova, LKQ, MSCI, — CNBC's Michelle Fox, Sarah Min, Jesse Pound Organizations: General Motors, General, GE Aerospace —, GE, PepsiCo, Novartis, JetBlue Airways —, Spotify, JPMorgan, Sunnova Energy, KeyBanc, FactSet Locations: U.S, LSEG . Cleveland, Cleveland

☆ Novartis lifts guidance after first-quarter results beat expectations
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: +2 min

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results. In a statement, it said 2024 net sales would likely grow by a high-single to low double-digit percentage with adjusted operating income expected to grow by a low double-digit to mid-teens percentage. It has previously predicted that adjusted operating income would increase by a "high single-digit" percentage with "mid single-digit" sales growth. Quarterly adjusted operating income gained 16% to $4.54 billion, beating an average analyst estimate of about $4.3 billion.

Persons: Bristol Myers, Giovanni Caforio, Joerg Reinhardt, Vas Narasimhan, Sandoz Organizations: Novartis, Institutes, Research, Bristol, Bristol Myers Squibb Locations: Cambridge , Massachusetts, U.S

☆ Tuesday's rapid fire: RTX, Pepsi, Nucor, Novartis and Cadence Design Systems
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTuesday's rapid fire: RTX, Pepsi, Nucor, Novartis and Cadence Design SystemsCNBC's Jim Cramer on Tuesday offered his thoughts on the recent earnings reports of RTX, PepsiCo, Nucor, Novartis and Cadence Design Systems.

Persons: Jim Cramer Organizations: Pepsi, Novartis, Cadence Design Systems, RTX, PepsiCo, Nucor

☆ Why this is perfect time to buy health-care stocks, one financial advisor says
▼ + stars: | 2024-04-23 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Health care shouldn't be overlooked as a place to buy amid the current market turmoil, according to Jamie Cox, managing partner at Harris Financial Group. He's been particularly interested in health care — pharma more specifically — as the industry feels tailwinds from artificial intelligence and the weight-loss drug boom. "The amount of money that the health care industry is making is being completely ignored by investors," Cox told CNBC Pro. "The noise of the short-term back-and-forth ... gives you good opportunity to buy high-quality companies, while people are just selling indiscriminately." For more diversified exposure, Cox recommended the Vanguard Health Care ETF (VHT) .

Persons: Jamie Cox, Cox, He's, FactSet, That's, they're, Johnson, Eli Lilly Organizations: Harris Financial Group, Federal Reserve, pharma, CNBC, Pharma, Novo Nordisk, Novartis, Pfizer, Swiss, Novo, Vanguard Health Care Locations: U.S

☆ Jim Cramer shares his thoughts on RTX, Pepsi, Nucor, Novartis and Cadence Design Systems
▼ + stars: | 2024-04-23 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +1 min

RTX : Shares were roughly flat after the aerospace and defense company delivered a quarterly earnings beat and reaffirmed its full-year 2024 outlook for sales, adjusted earnings and free cash flow. He goes out on an absolute high," Jim Cramer said, noting the strength in its Pratt & Whitney division. Nucor : The steelmaker's first-quarter earnings and sales came in lighter than expected, and its current-quarter outlook disappointed, as well. Cramer noted Nucor CEO Leon Topalian is set to appear on "Mad Money" later Tuesday, and he'll be seeking clarity around the impact pricing has had on the company. Cadence Design Systems : The semiconductor design software maker's second-quarter guidance came in light, saying customers are delaying orders due to hardware transition.

Persons: Jim Cramer's, Greg Hayes, Jim Cramer, Cramer, Leon Topalian, he'll, I've, Vas Organizations: CNBC, Club, Pratt & Whitney, PepsiCo, Novartis, Cadence Design Systems Locations: U.S, Swiss

☆ Stocks making the biggest premarket moves: General Motors, GE Aerospace, Novartis, JetBlue and more
▼ + stars: | 2024-04-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

The results were better than analysts' expectations of 65 cents per share on revenues of $15.14 billion, according to LSEG. UPS posted $1.43 adjusted earnings per share while analysts had estimated $1.29 earnings per share, according to LSEG. Danaher — The life sciences firm popped more than 8% after beating analysts expectations for its first-quarter results. Spotify — Shares rallied 8.4% after the music streaming company's first-quarter revenues beat analysts' expectations. Sherwin-Williams reported adjusted earnings per share of $2.17, missing the FactSet consensus estimate of $2.22.

Persons: General Motors, Nucor, Danaher, Lockheed Martin, LSEG, Sherwin, Williams, — Hakyung Kim, Tanaya Macheel, Alex Harring, Jesse Pound, Lisa Han Organizations: General, GM, GE Aerospace —, United Parcel Service, UPS, Pepsico —, Pepsico, Novartis — U.S, JetBlue Airways —, JetBlue, Wall Street, SAP — U.S, SAP, Revenue, Lockheed, —, Spotify Locations: Swiss, Wall Street Cleveland

☆ Drugmaker Novartis climbs 4.4% after guidance rise on sales of blockbuster drugs
▼ + stars: | 2024-04-23 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Signage for Novartis AG at a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals on Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results. Novartis' net sales rose 11% in the first three months of the year, while core operating income increased 22% over the same period. Narasimhan said the company continued to advance its drug pipeline in the first quarter, including treatments for prostate cancer and leukemia. "The momentum in our business and pipeline gives us continued confidence in our mid- and long-term growth outlook," he said.

Persons: Vas Narasimhan, Narasimhan Organizations: Novartis AG, Swiss, Novartis Locations: company's, Basel, Switzerland, London

☆ The US dollar is strengthening. Here’s what’s driving the rally and what it means for Americans
▼ + stars: | 2024-04-21 | by ( Bryan Mena | ) edition.cnn.com time to read: +7 min

What does the dollar rally mean internationally? The US Commerce Department releases March figures on new orders for durable goods. The US Commerce Department releases its first estimate of first-quarter gross domestic product. The US Labor Department reports the number of new applications for unemployment benefits in the week ended April 20. The US Commerce Department releases March figures on household spending, income and the Fed’s preferred inflation gauge.

Persons: it’s, Michelle Bowman, Bell, Claudio Irigoyen, It’s, Samantha Delouya, ”, eMarketer, Ross Benes, Wall, Read, Lockheed Martin, Raymond James, Northrop Organizations: Washington CNN, Federal Reserve, Bank of America, Netflix, Verizon, Truist, Albertsons, The Chicago Fed, Visa, Tesla, Pepsico, Novartis, UPS, Lockheed, Banco Santander, Spotify, General Motors, Halliburton, Global, US Commerce Department, Meta, IBM, Boeing, Chipotle, Hilton, Ford, Hasbro, Whirlpool, Wyndham, Microsoft, Mobile, Caterpillar, Comcast, Intel, P Global, Honeywell, Gilead, Northrop Grumman, Valero, Capital, Nasdaq, Southwest Airlines, American Airlines, Citizens Financial, US Labor Department, National Association of Realtors, Bank of Japan, Exxon Mobil, Chevron, HCA Healthcare, Colgate, Palmolive, Phillips, Charter Communications, University of Michigan Locations: Europe, Japan, China, Roku

☆ Loads of analysts cut their price targets on these 10 stocks ahead of earnings
▼ + stars: | 2024-04-18 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Analysts have lowered their expectations on several global stocks this week by cutting their price targets. The list of stocks includes auto stocks Tesla , Rivian and Aptiv , pharmaceutical firms Biogen and Novartis , energy companies EQT Corp and TotalEnergies , airline Deutsche Lufthansa and aerospace firm Boeing , and fast food giant McDonald's . The price target changes come ahead of the next earnings season covering the first quarter of this year. CNBC Pro screened for global stocks in the MSCI World index that have received price target downgrades over the past seven days and are yet to report earnings. Tesla Wall Street analysts from 15 firms downgraded their 12-month price targets for Tesla over the past week.

Persons: Elon Musk, Tesla's, Tesla, Stifel Nicholas, Johannes Braun, Marc Zeck, Samantha Subin, Michael Bloom Organizations: Novartis, EQT Corp, Deutsche Lufthansa, Boeing, CNBC Pro, Barclays, Lufthansa Locations: Stifel

☆ How a boutique bank that rode last year's healthcare M&A streak into the big leagues plans to continue to compete with the JPMorgan's of the world
▼ + stars: | 2024-03-13 | by ( Reed Alexander | ) www.businessinsider.com time to read: +9 min

It was more than double the value of the next-largest deal, a Japanese healthcare merger that clocked in at $22 billion. And, for its part, Seagen tapped advisors at two boutique firms: Centerview and MTS Health Partners. "We want to be the preeminent healthcare bank. Last year, during a healthcare M&A boom that's expected to continue this year, the bank onboarded 14 new staffers, including the partners, a company spokesperson said. Advertisement"We are absolutely in growth mode looking to have high-quality bankers who are capable of generating business off of this platform without all the accoutrements of a big bank," Weisenfeld continued.

Persons: Seagen, Andrew Weisenfeld, Goldman Sachs, Morgan Stanley, Dealogic, Weisenfeld, —, Curtis Lane, Bear, Daun Chung, Ryan Stewart, Reed Alexander Organizations: Service, Pfizer, Guggenheim, Centerview, MTS Health Partners, MTS, Goldman, JPMorgan, Bank of America, Partners, CTI, New, Bear Stearns, London Stock Exchange, Seagen, Medicines, Novartis, Chase Securities, Health Partners, Guggenheim Securities, Triple, SVB Securities, Solomon Partners, Citigroup Locations: Wall, New York City, Seattle

☆ European markets set for gains ahead of euro zone inflation data
▼ + stars: | 2024-03-01 | by ( Elliot Smith | ) www.cnbc.com time to read: +1 min

A TV presenter gets ready for the daily reporting from the floor of the German share price index DAX at the stock exchange in Frankfurt, Germany, November 15, 2023. LONDON — European markets are set to open higher on Friday to start the new trading month after a winning February, with euro zone inflation data due mid-morning. The European stock index notched an all-time high last month, powered by the 11 GRANOLAS large-cap stocks that made up half of the gains across the entire Stoxx 600. Focus will turn Friday to February's flash euro zone inflation reading, expected at 10 a.m. London time, with economists in a Reuters poll predicting the consumer price index rose 2.5% year on year, down from 2.8% in January. German consumer price inflation on Thursday came in line with forecasts at 2.7% year on year.

Persons: DAX Organizations: LONDON, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Focus, European Central Bank, ECB, Fed Locations: Frankfurt, Germany, London

☆ Judge rejects AstraZeneca’s challenge to Medicare drug price negotiations
▼ + stars: | 2024-03-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge on Friday rejected AstraZeneca 's legal challenge to Medicare's new power to negotiate the prices of certain costly prescription drugs with manufacturers. The decision is another win for the Biden administration in a bitter legal fight with the pharmaceutical industry over the constitutionality of those price talks. The opportunity to sell drugs to more than 49 million Medicare and Medicaid beneficiaries is a "powerful incentive" for manufacturers to participate in the price talks with the government, Connolly wrote. The ruling comes a month after a federal judge in Texas tossed a separate lawsuit challenging the price talks. On March 7, Bristol Myers Squibb, Novo Nordisk, Novartis and Johnson & Johnson will present their oral arguments to a federal judge in New Jersey in the same hearing.

Persons: AstraZeneca, Biden, AstraZeneca's, Colm Connolly, Connolly, Johnson Organizations: U.S . Department of Health, Human Services, Washington , D.C, Manufacturers, Supreme, District, AstraZeneca, Chamber of Commerce, Bristol Myers Squibb, Novo Nordisk, Novartis, Johnson, CNBC PRO Locations: Washington ,, Delaware, Texas, Ohio, New Jersey

☆ Meet the ‘Granolas,’ Europe’s answer to the Magnificent 7 stocks
▼ + stars: | 2024-02-27 | by ( Anna Cooban | ) edition.cnn.com time to read: +4 min

London CNN —The Magnificent 7 tech stocks have been a big part of the extraordinary US market rally. But there’s a rival group of companies powering European stocks to new heights with even better returns, by some measures. Dubbed the “Granolas,” those 11 companies accounted for 60% of the gains on Europe’s benchmark stock index over the past 12 months. They have even slightly outperformed the Magnificent 7 over a longer period, according to Goldman Sachs. Their standout performance has “raised the issue of concentration effects” in the region’s stock market, says Philip Lawlor, managing director of markets research at Wilshire Indexes.

Persons: London CNN —, Goldman Sachs, ASML, ” Goldman Sachs, Goldman Sachs, Guillaume Jaisson, Ozempic, ‘, Philip Lawlor, ” Lawlor Organizations: London CNN, GSK, Roche, Novartis, Novo Nordisk, L’Oréal, AstraZeneca, SAP, Sanofi, “, CNN, Danish, Wilshire Indexes, —, Deutsche Bank Locations: LVMH, Europe, France, Germany, Denmark, Switzerland, Netherlands, United Kingdom, United States

☆ The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
▼ + stars: | 2024-02-27 | by ( Elliot Smith | ) www.cnbc.com time to read: +3 min

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | ReutersOver the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. "From a Global point of view, the GRANOLAS have even outperformed the so-called Magnificent 7 over the past two years. Their (out)performance is even more impressive on a risk-adjusted basis: with a volatility 2x lower than for the Magnificent 7, the GRANOLAS help to boost the Sharpe ratio." "This suggests that, in Europe, nearly all revenue growth of the STOXX 600 will come from the GRANOLAS.

Persons: Goldman Sachs, Sanofi —, Goldman, Tim Hayes, Ned Davis, Hayes Organizations: Staff, Reuters, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Street, Ned, Ned Davis Research, CNBC Locations: Frankfurt, Germany, Europe

☆ New data shows asthma medicine may help reduce severe reactions in people with multiple food allergies
▼ + stars: | 2024-02-25 | by ( Amanda Musa | ) edition.cnn.com time to read: +9 min

CNN —A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. There is no cure for food allergies, and the only other FDA-approved treatment is Palforzia, an oral immunotherapy for peanut allergies in children between 4 and 17 years old. “But the reality is that most of our patients don’t just have peanut allergy,” Wood added. For people who have multiple severe food allergies and even moderate to severe allergic asthma, Casale says, Xolair might be the best treatment option. Xolair does not eliminate food allergies, and unlike with some environmental allergies such as pollen, many people never outgrow them, Casale added.

Persons: ”, Sharon Chinthrajah, “, ” Xolair, Robert Wood, ” Wood, Xolair, Wood, omalizumab, Thomas Casale, Palforzia, Casale, they’ve, ” Lindsey Mathias, Dr, Sanjay Gupta, Chinthrajah, “ We’re Organizations: CNN, New England, of Medicine, US Food and Drug Administration, Stanford University, of Allergy, Immunology, Johns Hopkins Children’s, Genentech, Novartis, FDA, National Institutes of Health, University of South, American Academy of Allergy Asthma, CNN Health, Xolair Locations: anaphylaxis, Eudowood, Johns, University of South Florida Tampa

☆ Job posts for workers without degrees are booming. The actual hiring doesn't always follow
▼ + stars: | 2024-02-19 | by ( Cheryl Winokur Munk | ) www.cnbc.com time to read: +10 min

But as data emerges on degreeless hiring, there are signs that some of these efforts may be falling short. It's based on limited data and doesn't consider alternative pathways that people without degrees use to join organizations, such as through apprenticeships and internships. But it's still a snapshot look at how some of the top employers in the U.S. are doing in their efforts to hire more workers based on skills versus degree attainment. Rather, it implies managers may be reticent to hire people without degrees, absent specific policies to assess these workers' skills. Companies that have been successful with skill-based hiring also articulate clearly the skills they require for a job, even before posting it.

Persons: it's, Matt Sigelman, What's, Sigelman, Schultz, Joseph Fuller, Fuller, Tyson, Lockheed Martin, Kroger, Stellantis, Backsliders, Meijer, Delta Organizations: Burning Glass Institute, Harvard Business School, Glass Institute, Workers, American, Foundation, Walmart, Apple, GM, Koch Industries, General Motors, Target, Tyson Foods, ExxonMobil, Yelp, Bank of America, Oracle, Companies, Lockheed, Stellantis, CNBC, Amazon, Nike, Delta, Uber, HSBC, Novartis, Delta Air Lines, US Foods Locations: U.S, Meijer

A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug omalizumab, became the first medication approved to reduce allergic reactions caused by accidental exposure to food triggers. An estimated 17 million people in the U.S. have the type of food allergies that can cause rapid, serious symptoms, including severe, whole-body reactions that are potentially deadly. Wood estimated that 25% to 50% of people with food allergies, particularly children and young adults, would elect to use Xolair. The drug has been used “off-label” to treat food allergies, said Dr. Ruchi Gupta, director of the Center for Food Allergy & Asthma Research at Northwestern University.

Persons: Xolair, ”, Robert Wood, Wood, Ruchi Gupta Organizations: U.S . Food, Drug Administration, Johns Hopkins Children’s Center, FDA, National Institutes of Health, Center for Food Allergy, Asthma Research, Northwestern University, drugmakers Novartis, Roche, Genentech, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S

☆ Asset manager names one under-the-radar market to buy when times are bad, giving 6 stock picks
▼ + stars: | 2024-02-08 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +4 min

"People recommend investing in the Swiss market during uncertain periods – like if you are expecting a recession. "Maybe in a bull market, Swiss equities are not going to be a huge outperformer globally — but they can generate positive returns. But in difficult times, Swiss equities, besides the U.S., is one of the markets to buy," Bänziger said. In her view, Swiss stocks benefit from the strong Swiss franc and a political system that fosters innovation in companies. Meanwhile, Bänziger believes Swiss Prime Site and PSP Swiss Property make good investments among small- and mid-caps, given the opportunities in the Swiss real estate sector.

Persons: Carla Bänziger, Bänziger, Stocks Organizations: U.S . Federal, that's, CNBC Pro, Swiss, State Secretariat, Economic Affairs, Swiss Re, SIX Swiss Exchange, Dow Jones International Real, ABB, Nestle, Roche, Novartis Locations: that's Switzerland, Swiss, Zurich, U.S, Switzerland, Germany, China, Europe

☆ Novartis acquiring cancer drug developer Morphosys for €2.7 billion
▼ + stars: | 2024-02-05 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis acquiring cancer drug developer Morphosys for €2.7 billionCNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.

Persons: Steve Kovach Organizations: Novartis

☆ Novartis CEO Vasant Narasimhan on Q4 earnings miss
▼ + stars: | 2024-02-01 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO Vasant Narasimhan on Q4 earnings missNovartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's quarterly earnings results, the company's warning about losing exclusivity in some products, and if the sector will be active in M&A.

Persons: Vasant Narasimhan Organizations: Novartis

☆ Novartis misses Q4 net income expectations, extends forecast
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Swiss drugmaker Novartis reported a 6% gain in fourth-quarter adjusted net income on Wednesday, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, it said in a statement, missing analysts' estimate of about $3.3 billion, as per LSEG data. Novartis also extended its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings. CEO Vas Narasimhan previously led a push to cut jobs and focus on fewer therapeutic areas and geographic markets, before spinning off and listing generic drugs business Sandoz late last year.

Persons: Sandoz, Vas Narasimhan Organizations: Novartis

Search resuls for: "Novartis"

25 mentions found